LoneStar Heart reports additional positive 6 month data from the AUGMENT-HF trial at the American College of Cardiology meeting in San Diego, CA. Click here to view slide presentation and the interview with Dr. Stephan Anker.
News and Announcements
LoneStar Heart Reports Significant Improvement in Health Status of Advanced Heart Failure Patients Treated with Algisyl-LVR® Cardiac Hydrogel Implants
Outcomes of the AUGMENT-HF Trial of Algisyl-LVR for Advanced Heart Failure Patients Presented at American Heart Association’s Clinical Science Special Reports
LoneStar Heart Receives European Approval to Market its Algisyl-LVR® Hydrogel Implant for the Treatment of Advanced Heart Failure
Implantable Gel May Revolutionize the Treatment of Patients Who Lose the Ability to Pump Blood Efficiently to the Body
LoneStar Heart Completes Recruitment for Randomized Clinical Trial of Algisyl-LVR® Hydrogel Implant for Advanced Heart Failure
Six-month Outcomes of AUGMENT-HF Multicenter Study to Be Presented by Yearend
Algisyl-LVR® to be the subject of two scientific presentations at the 9th Conference on Cell Therapy for Cardiovascular Disease in New York City
Watch a Video Interview following the report on the AUGMENT-HF heart failure clinical trial of Algisyl-LVR® presented at the 2013 Scientific Sessions of the American Heart Association in Dallas
LoneStar Heart Reports Positive Interim Results of Algisyl-LVR® for Advanced Heart Failure at AHA’s Late-Breaking Clinical Trials Sessions
An article has just been published in International Journal of Cardiology (In Press, Online Date: February 8th, 2013).
LoneStar Heart Inc.today announced the completion of an up to $20 million milestone-based equity financing to support the clinical testing and regulatory clearance of its lead product, Algisyl-LVR, a single-use, self-gelling biopolymer implanted into the heart’s left ventricle during surgery for the treatment of advanced heart failure. Themes Investment Partners (“Themes”), a Hong Kong-based private equity fund focused on China markets, led the round. The new financing brings up to $35 million in equity funding since the company’s founding in June 2010.
Press release - LoneStar Heart Inc. today announced the first patient was treated in the company’s international multi-center AUGMENT-HF clinical trial of Algisyl-LVR at IRCCS San Raffaele Pisana and at Umberto I Policlinico, both located in Rome, Italy.
LoneStar Heart Presents Abstract at the Annual Meeting of the Heart Failure Society of America. The text of the abstract is available from the Journal of Cardiac Failure here.
LoneStar Heart, Inc. Featured in Emerging Company Profile in BioCentury Magazine.